Immunome, Inc. (NASDAQ:IMNM) Receives $29.80 Average Target Price from Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM) have been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $29.80.

A number of research analysts have recently weighed in on IMNM shares. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Tuesday, May 14th. Piper Sandler started coverage on Immunome in a research report on Friday, May 31st. They set an “overweight” rating and a $27.00 price objective on the stock. JPMorgan Chase & Co. started coverage on Immunome in a research report on Tuesday, April 30th. They set an “overweight” rating and a $24.00 price objective on the stock. Finally, Guggenheim started coverage on Immunome in a research report on Monday, April 15th. They set a “buy” rating and a $35.00 price objective on the stock.

Insider Buying and Selling

In other Immunome news, Director Jean Jacques Bienaime purchased 2,000 shares of the stock in a transaction that occurred on Tuesday, May 21st. The shares were bought at an average cost of $13.57 per share, with a total value of $27,140.00. Following the acquisition, the director now owns 9,615 shares in the company, valued at $130,475.55. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. EntryPoint Capital LLC increased its stake in Immunome by 21,864.0% in the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after acquiring an additional 5,466 shares during the last quarter. Jump Financial LLC bought a new stake in Immunome in the 4th quarter worth approximately $172,000. Sei Investments Co. bought a new stake in Immunome in the 1st quarter worth approximately $469,000. Clear Creek Financial Management LLC bought a new stake in Immunome in the 1st quarter worth approximately $547,000. Finally, California State Teachers Retirement System bought a new stake in Immunome in the 1st quarter worth approximately $807,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $12.12 on Friday. The stock has a market capitalization of $726.84 million, a price-to-earnings ratio of -1.61 and a beta of 1.79. The stock’s 50-day simple moving average is $14.19 and its two-hundred day simple moving average is $17.16. Immunome has a 52-week low of $6.13 and a 52-week high of $30.96.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.46. The business had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $4.00 million. Immunome had a negative return on equity of 37.33% and a negative net margin of 1,829.44%. As a group, equities analysts forecast that Immunome will post -1.45 earnings per share for the current fiscal year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.